Oasmia Pharmaceutical AB (STO:OASM) (FRA:OMAX.GR) announced on Friday the appointment of Francois Martelet as the new CEO of the company.
Dr Martelet, who has extensive international experience of leading pharmaceutical companies, replaces Sven Rohmann, who has been acting CEO during a crucial transition period. Rohmann will remain in his position as board member and will continue to play an active role in the company's commercialisation strategy going forward.
Martelet has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive roles at senior level at Roche, Eli Lilly, Novartis and MSD. He has been based in six countries in Europe (including Sweden) and in the US.
Oasmia Pharmaceutical develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886